Melanocortin Receptors: MC1R, MC3R and MC4R in Research

The five melanocortin receptors, MC1R through MC5R, are all class A G-protein-coupled receptors signaling through Gs to raise intracellular cAMP. They also share one ancestral ligand family: the melanocortins cleaved from proopiomelanocortin (POMC) — alpha-MSH, beta-MSH, gamma-MSH and ACTH. That shared ancestry is the central complication of the field. Because all five subtypes read overlapping ligands through a conserved core motif, what a melanocortin receptor agonist does is determined not by its potency but by its selectivity — which receptors it activates, and in what rank order. Two compounds can share an identical macrocycle and signal very differently because one of them also engages MC1R.

The five melanocortin receptors and what each one does

Mountjoy and colleagues reported the cloning of the first melanocortin receptor genes in 1992 (PMID 1325670); the fourth and fifth subtypes followed from Gantz and colleagues in 1993 and 1994 (PMID 8392067, PMID 8185570). The subtypes diverge sharply in expression and in what the literature associates with them.

Receptor	Principal expression	Associated in published work with	Reference
MC1R	Melanocytes; some immune cells	Eumelanin synthesis and pigmentation; loss-of-function variants track with red hair and fair skin	PMID 7581459
MC2R	Adrenal cortex	The ACTH receptor; requires the MRAP accessory protein to reach the cell surface	PMID 1325670, PMID 15654338
MC3R	Hypothalamus, limbic system, periphery	Energy partitioning and nutrient sensing; more recently, childhood growth and the timing of puberty	PMID 34732894
MC4R	CNS, dense in the paraventricular nucleus	Energy homeostasis and appetite; the most common monogenic cause of severe early-onset obesity	PMID 12646665
MC5R	Exocrine tissue, including sebaceous gland	Exocrine gland regulation; knockout mice show defective sebum production	PMID 9413988

Why selectivity is the whole story for a melanocortin receptor agonist

All melanocortin ligands share a core recognition motif: the His-Phe-Arg-Trp tetrapeptide at residues 6–9 of alpha-MSH. All five receptors read this same message sequence, so an alpha-MSH analog built around it engages several subtypes by default. MC2R is the one exception — it is the ACTH receptor and does not respond to alpha-MSH, which is the only separation this family gives away for free. Everything else has to be engineered on top of the core rather than discovered within it.

Structure-activity reviews describe the standard levers: D-amino acid substitution, cyclization to lock the backbone into one preferred conformation, and modification of the termini. Work on beta-MSH-derived MC4R agonists documents how narrow the tolerances are (PMID 17584126), and the parallel effort to build MC3R-selective ligands proved harder still, because the MC3R and MC4R pockets are closely related (PMID 17584128). Melanocortin receptor selectivity here is a matter of degree: published compounds are usually described by a rank order of potency, not a clean single-target claim.

MC4R is the one subtype with a selective agonist carried through to approval: setmelanotide, evaluated in single-arm, open-label phase 3 trials in severe obesity from LEPR or POMC deficiency (PMID 33137293). That program is the reference point for MC4R agonist research — and its population was narrow: genetic lesions upstream of the receptor.

One terminal group separates the two best-known melanocortin peptides

Bremelanotide, also called PT-141, is described in its FDA prescribing information as a cyclic heptapeptide with the structure Ac-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys-OH) — an acetylated amino terminus and a free acid at the carboxyl terminus. Melanotan II carries a primary amide at that position; the acetylated N-terminus, the D-Phe substitution and the Asp–Lys lactam bridge are otherwise shared. The two differ by that terminal group and by roughly one mass unit, the label giving bremelanotide a free-base molecular weight of 1025.2 against 1024 for melanotan II. Compound-level detail sits in the PT-141 and Melanotan II monographs; at the receptor level, that small change shifts the balance of subtype engagement without removing MC1R activity from either compound.

What the bremelanotide trial data showed

RECONNECT is the phase 3 program for bremelanotide: two identically designed, randomized, double-blind, placebo-controlled multicenter studies in premenopausal women with hypoactive sexual desire disorder (PMID 31599840). Of 1,267 women randomized, 1,247 were in the safety population and 1,202 in the modified intent-to-treat population. The studies ran 24 weeks, with co-primary endpoints on the Female Sexual Function Index desire domain and item 13 of the Female Sexual Distress Scale.

Both co-primary endpoints reached statistical significance: desire rose 0.30 in one study and 0.42 in the other (0.35 integrated), and distress related to low desire fell 0.37 and 0.29 (−0.33 integrated). The differences are small in absolute terms on both instruments — the honest reading of the bremelanotide trial data. A later prespecified and integrated subgroup analysis reported the direction of effect held across age, weight, BMI and bioavailable testosterone quartiles, with few exceptions (PMID 35230162).

The more instructive part of that record is the label's pharmacology section, which states that bremelanotide nonselectively activates several subtypes with the order of potency MC1R, MC4R, MC3R, MC5R, MC2R — MC1R first — and notes that binding at MC1R leads to melanin expression and increased pigmentation. The compound taken furthest through clinical development in this class is not subtype-selective.

That signal tracked how often the receptor was stimulated. The label reports that in the phase 3 trials, which capped monthly exposure, focal hyperpigmentation — including of the face, gingiva and breasts — occurred in 1% of treated participants and none on placebo. The same label describes a separate study in which it was instead given on consecutive days across an eight-day period; there, 38% developed focal hyperpigmentation, and among those continuing a further eight consecutive days, an additional 14% developed new pigmentary changes. Participants with dark skin were more likely to be affected, and resolution after discontinuation was not confirmed in all cases.

That contrast — 1% against 38% for the same molecule — is the most instructive number: off-target engagement is not a fixed property of a compound but a function of exposure pattern.

The documented safety literature on non-selective melanotan compounds

The published safety record for unlicensed melanotan compounds is case reports and small series, not controlled trials. They establish temporal association, not causation, and carry no denominator, so they cannot support any statement about incidence. With that limit stated, the signals cluster predictably:

• Melanocytic and naevus changes. A 2009 BMJ report described changes in moles after use of an unlicensed tanning injection (PMID 19174439); the pattern recurs in reviews of melanotropic peptides (PMID 20545686) and eruptive melanocytic nevi (PMID 31119650). Australian dermatologists have flagged unregulated melanotan-II use as a public-health concern (PMID 28905366).
• Mucosal pigmentation. Recent reports describe pigmentary change in oral mucosa and raise the question of mucosal melanoma risk (PMID 40210573) — a question the case literature poses without answering.
• Urological and vascular events. Priapism appears in independent case reports (PMID 30796078, PMID 33460908), consistent with central melanocortin involvement in erectile signaling. A case report with literature review has also raised renal infarction (PMID 31953620).

The pigmentation signal deserves particular weight because two independent lines converge on it: the uncontrolled case literature, and the frequency-dependent hyperpigmentation in the controlled record of a closely related compound. Convergence across designs is worth more than either source alone.

Identity and purity as a research variable

A second problem sits underneath that literature: almost all of it involves material obtained outside a regulated supply chain, so the reports cannot cleanly attribute any effect to the named molecule.

A 2024 forensic toxicology paper makes this concrete. A laboratory received vials labelled "Melanotan II" and found identification unexpectedly difficult: at 1,024 Da the compound sits above the 1,000 Da ceiling many instrument methods are configured for, it presents as multiply charged, and no reference UV spectrum was available. Once a reference standard confirmed identity, the purity of the vial contents was determined to be 30% (PMID 39302005).

Where pharmacology is decided by which subtypes a ligand engages and in what order, an uncharacterized 70% of a vial is not a rounding error. Solid-phase synthesis of a constrained cyclic compound yields truncations, deletion sequences and incompletely cyclized material, and some byproducts retain the His-Phe-Arg-Trp core while losing the conformational constraints engineered in to bias selectivity. A less pure lot is not simply a weaker lot — it can be a different mixture of receptor activities. That is why every Merit lot ships with an HPLC purity certificate and mass-spectrometry identity confirmation, each published so any lot's certificate of analysis can be checked against the record.

Treat "melanocortin agonist" as an incomplete description. What this literature supports is a rank order of subtype potency, observed under one exposure pattern, in one model. Before two published results are compared, both deserve a check for the same rank order, the same exposure pattern, and material that was identified and quantified. In this class more than most, the receptor map and the certificate are the same question asked twice.

Notes

This is a summary of published receptor pharmacology and clinical literature. It is not a recommendation for any research protocol or design, and it does not describe preparation or administration. For research use only. Not for human or veterinary use.

Selected references

1. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science 1992;257:1248–1251. PMID: 1325670
2. Gantz I, Miwa H, Konda Y, et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993;268:15174–15179. PMID: 8392067
3. Gantz I, Shimoto Y, Konda Y, et al. Molecular cloning, expression, and characterization of a fifth melanocortin receptor. Biochem Biophys Res Commun 1994;200:1214–1220. PMID: 8185570
4. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11:328–330. PMID: 7581459
5. Metherell LA, Chapple JP, Cooray S, et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat Genet 2005;37:166–170. PMID: 15654338
6. Chen W, Kelly MA, Opitz-Araya X, et al. Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 1997;91:789–798. PMID: 9413988
7. Farooqi IS, Keogh JM, Yeo GS, et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003;348:1085–1095. PMID: 12646665
8. Yan LZ, Hsiung HM, Heiman ML, et al. Structure-activity relationships of beta-MSH derived melanocortin-4 receptor peptide agonists. Curr Top Med Chem 2007;7:1052–1067. PMID: 17584126
9. Hruby VJ, Cai M, Cain JP, Mayorov AV, Dedek MM. Design, synthesis and biological evaluation of ligands selective for the melanocortin-3 receptor. Curr Top Med Chem 2007;7:1107–1119. PMID: 17584128
10. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol 2019;134:899–908. PMID: 31599840
11. Simon JA, Kingsberg SA, Portman D, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health 2022;31:391–400. PMID: 35230162
12. Clément K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol 2020;8:960–970. PMID: 33137293
13. Lam BYH, Williamson A, Finer S, et al. MC3R links nutritional state to childhood growth and the timing of puberty. Nature 2021;599:436–441. PMID: 34732894
14. Langan EA, Ramlogan D, Jamieson LA, Rhodes LE. Change in moles linked to use of unlicensed "sun tan jab". BMJ 2009;338:b277. PMID: 19174439
15. Langan EA, Nie Z, Rhodes LE. Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'? Br J Dermatol 2010;163:451–455. PMID: 20545686
16. Adler NR, Dowling JP, Pan Y. The unregulated use of melanotan-II is of public health interest to Australian dermatologists. Australas J Dermatol 2017;58:327–329. PMID: 28905366
17. Burian EA, Jemec GBE. Eruptive Melanocytic Nevi: A Review. Am J Clin Dermatol 2019;20:669–682. PMID: 31119650
18. Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep 2019;12:e227644. PMID: 30796078
19. Mallory CW, Lopategui DM, Cordon BH. Melanotan Tanning Injection: A Rare Cause of Priapism. Sex Med 2021;9:100298. PMID: 33460908
20. Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep 2020;9:159–161. PMID: 31953620
21. Yassin Alsabbagh A, Bhujel N, Singh RP. Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? Int J Oral Maxillofac Surg 2025;54:806–808. PMID: 40210573
22. Deville M, Charlier C. Barbie drug identification: Not a child's play. J Forensic Sci 2024;69:2331–2338. PMID: 39302005
23. VYLEESI (bremelanotide) injection — US prescribing information, sections 5.2, 11 and 12.1.